Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

prnasiaJuly 29, 2021

Tag: I-Mab , efineptakin alfa , TNBC , HNC

PharmaSources Customer Service